Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025), reflecting the recognition of its clinical value by the National Healthcare Security Administration [1][2]. Group 1: Product Information - The product Sitagliptin Metformin Extended-Release Tablets (II) has been included in the National Medical Insurance Catalog (2025) under a national negotiation renewal format [1]. - The inclusion is expected to enhance the affordability and accessibility of the drug for patients, thereby promoting its market expansion and increasing sales volume [1]. Group 2: Impact on the Company - The renewal of the product's inclusion in the National Medical Insurance Catalog is anticipated to have a positive impact on the company's long-term operational development [1]. - The company plans to actively cooperate in implementing the medical insurance policy to benefit more patients [1]. Group 3: Implementation Timeline - The National Medical Insurance Catalog (2025) will officially take effect on January 1, 2026, with specific details on reimbursement standards and policies to be announced by relevant government departments [2].

Core Viewpoint - The inclusion of two drugs, JinSaiZeng and MeiShiYa, in the National Medical Insurance Directory for 2025 reflects the recognition of their clinical value and innovation by the National Healthcare Security Administration, which is expected to enhance market promotion and sales scale for the company [1][4]. Group 1: Drug Information - JinSaiZeng (Generic name: JinPei Growth Hormone Injection) is a long-acting growth hormone approved in January 2014, indicated for various growth disorders in children and is the only long-acting growth hormone product in China with over 150,000 real-world data supporting its long-term efficacy and safety [1]. - MeiShiYa (Generic name: Acetate Medroxyprogesterone Oral Suspension) is developed by Baosheng Pharmaceutical and authorized for exclusive distribution by JinSai Pharmaceutical, indicated for appetite loss in patients with acquired immunodeficiency syndrome and cachexia in cancer patients [3]. Group 2: Insurance Payment Scope - JinSaiZeng is covered for children with endogenous growth hormone deficiency (GHD) causing growth retardation, with the insurance payment standard effective from January 1, 2026, to December 31, 2027 [2]. - MeiShiYa is covered for appetite loss in patients with acquired immunodeficiency syndrome and significant weight loss due to cachexia in cancer patients, with the same insurance payment standard effective period [4]. Group 3: Impact on the Company - The inclusion of these drugs in the National Medical Insurance Directory is expected to positively impact the company's market presence and sales performance, although the exact financial implications remain uncertain at this time [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告由嘉和生物藥業（開曼）控股有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以知會本公司股東及潛在投資者有關本集團最新業務更新。 （股份代號：6998） 來羅西利(GB491)納入國家醫保藥品目錄 本公司董事會（「董事會」）宣佈，來羅西利(GB491)已納入由國家醫療保障局於 2025年12月7日發佈的《國家基本醫療保險、生育保險和工傷保險藥品目錄（2025 年）》（「國家醫保藥品目錄」）。此乃來羅西利(GB491)首次被納入國家醫保藥品目 錄。新版國家醫保藥品目錄將於2026年1月1日起生效。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） 自願公告 嘉和生物藥業（開曼）控股有限公司 執行董事及首席財務官 翁承毅先生 香港，2025年12月8日 於本公告日期，董事會由六(6)名董事組成，即執行董事 ...

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received inclusion of its self-developed JinSaiZeng (growth hormone injection) and the co-introduced Meishiya (medroxyprogesterone acetate oral suspension) into the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] Group 1 - The inclusion of these drugs reflects national recognition and is expected to facilitate market promotion and enhance sales scale [1] - The medical insurance payment standards will be effective from January 1, 2026, to December 31, 2027 [1] - The impact on the company's performance from this inclusion is currently difficult to estimate [1] Group 2 - The new drug list will be implemented starting January 1, 2026, with reimbursement details to be determined by government announcements [1]

Core Viewpoint - The company announced that its self-developed monoclonal antibody injection, Sairiqi (Jinlixi), has been successfully included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, effective from January 1, 2026, with an agreement valid until December 31, 2027 [1] Group 1 - The drug is classified as a Class I biological product and a Class B prescription drug, intended for the treatment of moderate to severe plaque psoriasis and ankylosing spondylitis [1] - The corresponding indications for the drug are expected to receive market approval in August 2024 and January 2025, respectively [1] - Inclusion in the medical insurance list may facilitate the market promotion and sales of the product, although sales are subject to various influencing factors, leading to uncertainty [1]

Core Viewpoint - Junshi Biosciences announced that its products, Toripalimab Injection (Tuoyi®) has received two new indications, and the drug Oncorine Injection (Junsida®) has been successfully included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) under Category B, effective from January 1, 2026 [1] Group 1 - The inclusion of Toripalimab's 12 approved indications in the insurance catalog enhances the affordability and accessibility of the product [1] - Oncorine Injection is being included in the insurance catalog for the first time, which is expected to boost its market penetration [1] - All four commercialized products of the company are now covered by medical insurance, facilitating market promotion [1]